Although its role is still under debate, the MAPT A152T variant significantly increases the risk for FTD and AD and it has been described in rare patients with PSP or CBD (Coppola et al., 2012; Kara et al., 2012; Biswas et al., 2016). This evidence concerns the gene MAPT and Alzheimer disease.